Navigation Links
Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
Date:2/9/2009

LAIYANG, China, Feb. 9 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the American Arbitration Association ("AAA") rendered a decision rejecting requests by Capital Research Group, Inc. ("CRG") to award it $13.8 million and by Capital Research Group Partners, Inc. ("CRGP") to award it $13.7 million related to an alleged breach of three consulting agreements.

On February 2, 2009, after the arbitration panel heard CRG and CRGP's claims, and Genesis' counterclaims, the panel awarded a net total of $980,070.50 to CRG and CRGP jointly, representing less than four percent (4%) of the damages sought by Claimants. The AAA also denied the Claimants' requests for costs and pre-judgment interest, stating that once the award was satisfied, CRG and CRGP would have no further claims against Genesis stock or other property that were the subject of the arbitration.

A few days before the decision by the AAA, all remaining demands for arbitration filed against Genesis by related parties China West, LLC and China West II, LLC were withdrawn.

"While we are disappointed that any damages would be levied against the Company, we believe that this outcome has resulted in minimal negative impact on Genesis," said Mr. Wubo Cao, CEO of Genesis. "The successful defense of CRG and CRGP's claims, along with the withdrawal by China West and China West II of their remaining demands for arbitration will allow us to once again turn our full attention to managing and growing Genesis."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    Genesis Pharmaceuticals Enterprises, Inc.
     Ms. Elsa Sung, CFO
     Phone:    +1-954-727-8435
     Email:    elsasung@jiangbo.com
     Web site:http://www.genesispharmaceuticals.com

     CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone:    +1-646-213-1915
     Email:    crocker.coulson@ccgir.com
     Web site:http://www.ccgirasia.com

'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
2. Angiogenesis linked to poor survival in patients with rare type of ovarian cancer
3. Genesis Pharmaceuticals Enters Into Agreement to Purchase Hongrui Pharmaceuticals, and Acquire 22 New Traditional Chinese Medicines
4. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
5. What is the pathogenesis of C. jejuni-related disease?
6. ThermoGenesis Introduces New Cell Separation Technology for Veterinary Use at Major Equine Convention
7. ThermoGenesis Corp. Provides Updated Information for Conference Call/Webcast to Discuss Management Transition
8. ThermoGenesis Corp. Schedules Conference Call/Webcast to Discuss Management Transition
9. ThermoGenesis Announces Management Transition; Provides Update on Operational Milestones
10. Organogenesis Receives Two Prestigious Awards for Economic Impact and Manufacturing Excellence
11. China West II Files Suit Against Genesis Pharmaceuticals and Capital Research Group Inc, Announces Conference Call Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... Healthy eating isn’t always easy. Currently, more than 80 percent of ... many Americans overeat refined grains and sugar. This trend may help explain why the obesity ... U.S. are obese. , As a culture, we seem to have food on the brain ...
(Date:7/27/2017)... ... July 27, 2017 , ... The Freedom from Cancer Startup ... around 117 breakthrough inventions from 55 institutions, including the National Institutes of Health ... Biomedical Imaging and Bioengineering), the United States Army, and more than fifty American ...
(Date:7/27/2017)... GREENWOOD VILLAGE, CO (PRWEB) , ... July 27, 2017 , ... ... According to the National Funeral Directors Association, this trend is expected to continue with ... this trend, there is a growing demand for new innovations that enable families to ...
(Date:7/26/2017)... ... July 26, 2017 , ... An inventor from Salisbury, N.C., knows the ... seen an effective and dignified way to keep leeches in place during therapy," she ... This invention provides an effective way to keep a leech in place on the ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley ... major advancement in drug therapy for patients living with relapsing and primary multiple ... novel B cell targeted therapy that has been proven to significantly reduce signs ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology: